Abbreviations ARR: Absolute risk reduction ASCVD: Atherosclerotic cardiovascular disease CANVAS: Canagliflozin Cardiovascular Assessment Study CKD: Chronic kidney disease CVD: Cardiovascular disease CVOT: Cardiovascular outcomes trial DKA: Diabetic ketoacidosis DPP-4: Dipeptidyl peptidase-4 DPP-4i: Dipeptidyl peptidase-4 inhibitor DSMES: Diabetes self-management education and support EMPA-REG OUTCOME: Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients ESRD: End-stage renal disease EXSCEL: Exenatide Study of Cardiovascular Event Lowering GLP-1: Glucagon-like peptide-1 GLP-1 RA: Glucagon-like peptide-1 receptor agonist HF: Heart failure LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of of Cardiovascular Outcomes Results MACE: Major adverse cardiac events MI: Myocardial infarction MNT: Medical nutrition therapy RCT: Randomised clinical trial SGLT2: Sodiumglucose cotransporter-2 SGLT2i: Sodiumglucose cotransporter-2 inhibitor SMBG: Self-monitoring of blood glucose SU: Sulfonylurea SUSTAIN 6: Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes T2DM: Type 2 diabetes mellitus TZD: Thiazolidinedione UKPDS: UK Prospective Diabetes Study References Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS et al (2016) Shared decision making in endocrinology: present and future directions
"My hubby, who never notices when I cut my hair
GLP-1 is an incretin hormone, produced by L cells to regulate glucose and energy homeostasis via GLP-1R binding [9]
A pour-on-after technique competes against active closure
Circ_0001093 promotes glutamine metabolism and cancer progression of esophageal squamous cell carcinoma by targeting mir-579-3p/glutaminase axis
Zhang, R., Palumbo, A., Kim, J
.png)
